Stockreport

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Genelux Corporation  (GNLX) 
PDF – Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Posi [Read more]